InSphero at the Global Summit on Regulatory Science 2025
Join us at the Global Summit on Regulatory Science in Lausanne, Switzerland and discover how we're pioneering the use of NAMs and 3D in vitro models.
The Global Summit on Regulatory Science works to create expansive collaborations that prioritize the design of innovative technologies that can produce reliable and scalable data. Our advanced 3D in vitro models are reducing the need for non-physiologically relevant animal models and changing the future of drug development and regulatory science.
Join us at the Global Summit for Regulatory Science 2025 in Lausanne, Switzerland from Monday, September 15 to Wednesday, September 17.
Meet our Team at the Global Summit on Regulatory Science 2025


Madhu Nag, PhD
Chief Scientific Officer
Madhu Nag, PhD
Chief Scientific Officer
Madhu Lal-Nag earned her Doctor of Philosophy (PhD) in Molecular and Cellular Oncology from George Washington University and her master’s in Bioscience Business from Keck Graduate Institute.
She aims to bridge the gap between the academic and the translational aspects of cutting-edge science in oncology, metabolic diseases, and investigative toxicology. Using the results of current therapeutic regimens to creatively translate cutting-edge research to immediately serve patient needs.Director of the Trans NIH RNAi Facility at the National Center for Advancing Translational Sciences (NCATS/NIH) and Program Director at USFDA.


Scientific Talk at the Global Summit on Regulatory Science 2025
Navigating the Future in the NAMS Ecosystem: Scientific Advances Driving Non-Animal Approaches in Toxicology and Drug Development
Date: Wednesday, September 17| 14:20 -14:40
Location: Campus Level, Auditorium B


Madhu Nag, PhD
Chief Scientific Officer
Madhu Nag, PhD
Chief Scientific Officer
Madhu Lal-Nag earned her Doctor of Philosophy (PhD) in Molecular and Cellular Oncology from George Washington University and her master’s in Bioscience Business from Keck Graduate Institute.
She aims to bridge the gap between the academic and the translational aspects of cutting-edge science in oncology, metabolic diseases, and investigative toxicology. Using the results of current therapeutic regimens to creatively translate cutting-edge research to immediately serve patient needs.Director of the Trans NIH RNAi Facility at the National Center for Advancing Translational Sciences (NCATS/NIH) and Program Director at USFDA.

